Israel - hebreo - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

Israel - hebreo - Ministry of Health

astrazeneca (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - ספריי לאף - b/phuket/3073/2013 (b/yamagata lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/darwin/9/2021 (h3n2)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 7 ±0.5 log10 ffu^a / 0.2 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - flumist quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses ad type b viruses contained in the vaccine. flumist quadrivalent is approved for use in persons 2 through 49 years of age.

Israel - hebreo - Ministry of Health

astrazeneca (israel) ltd - selumetinib as hyd-sulfate - קפסולה קשיחה - selumetinib as hyd-sulfate 10 mg - selumetinib

Israel - hebreo - Ministry of Health

astrazeneca (israel) ltd - selumetinib as hyd-sulfate - קפסולה קשיחה - selumetinib as hyd-sulfate 25 mg - selumetinib

Israel - hebreo - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ethinylestradiol; gestodene - טבליות מצופות - ethinylestradiol 0.020 mg; gestodene 0.075 mg - gestodene and estrogen - gestodene and estrogen - contraceptive.

Israel - hebreo - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ethinylestradiol; gestodene - טבליה - gestodene 0.075 mg; ethinylestradiol 0.030 mg - ethinylestradiol - ethinylestradiol - contraception.

Israel - hebreo - Ministry of Health

pfizer pharmaceuticals israel ltd - pegvisomant - אבקה וממס להכנת תמיסה להזרקה - pegvisomant 10 mg - pegvisomant - pegvisomant - treatment of patient with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize igf-i concentrations or was not tolerated.

Israel - hebreo - Ministry of Health

pfizer pharmaceuticals israel ltd - pegvisomant - אבקה וממס להכנת תמיסה להזרקה - pegvisomant 15 mg - pegvisomant - pegvisomant - treatment of patient with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not narmalize igf-i concentrations or was not tolerated.

Israel - hebreo - Ministry of Health

pfizer pharmaceuticals israel ltd - pegvisomant - אבקה וממס להכנת תמיסה להזרקה - pegvisomant 20 mg - pegvisomant - pegvisomant - treatment of patient with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not narmalize igf-i concentrations or was not tolerated.

Israel - hebreo - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus